In this unique one-hour webinar, Dr. Jena outlines a broader framework for assessing value to improve identification of not only the highest-value treatments, but also low-value therapies on which spending can safely be reduced.
In Spotlight on Market Access, Precision senior research economist James Baumgardner provides his perspective on HHS’ proposed changes to Medicare Part D loosening government restrictions on 4 protected drug classes, including those to treat HIV. Baumgardner cautions the rule changes “directly imperils those with HIV who have Medicare as their source of health coverage,” and urges greater adoption of HIV prevention efforts, including the use of new PrEP treatments that can greatly reduce the risk of acquiring HIV.
Harnessing four key strategies, HHS set a goal to virtually eliminate HIV within 10 years—a goal experts believe is achievable. Yet, as reported in Spotlight on Market Access, other HHS policies may be working against that goal. James Baumgardner, senior research economist at Precision Health Economics, shares his insights.
In a special feature focused on drug pricing solutions and value, PharmaLive’s Christiane Truelove talks with Precision subject matter experts Jeremy Schafer and Jason Shafrin, who offer their perspectives on the complex landscape.
As the spotlight on manufacturers’ raising the prices of therapies already on the market shows no sign of dimming, one industry group recently unveiled its intentions to dig a little deeper into the topic. The Institute for Clinical and Economic Review (ICER) says it will create a series of so-called Unsupported Price Increase (UPI) reports that will examine whether price increases are justified.
For more information, or to learn how to change your cookies preferences, please click here.